Pilar S. A.
- Country
- Spain
- Department
- Neurology
Research Overview
- An adaptive, Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson’s disease
- Long-Term Safety and Tolerability Assessment of Trospium Chloride and Xanomeline Tartrate in Psychosis Associated with Alzheimer's Disease
- Phase 3b Open-Label Randomized Study of IPX203 Versus Immediate-Release Levodopa/Carbidopa in Advanced Parkinson's Disease with Motor Fluctuations
Data & Insights
Has run more than one trial at 5 of 108 partner sites.
Specializations
Neurodegenerative Disorders
The investigator specializes in the study of early-stage Parkinson's disease, with particular emphasis on innovative therapeutic approaches for managing this progressive neurological condition.
- Early-stage Parkinson's Disease management
- Neurological immunotherapy
- Disease-modifying interventions
Their research explores immune responses and therapeutic interventions in neurodegenerative conditions.
Immunological Research
The investigator focuses on immunological responses and antibody-mediated therapies in neurological conditions.
- Vaccine immunogenicity
- Serum antibody analysis
- Immune system modulation
Their work encompasses the evaluation of immune responses in neurological disease treatments.
Clinical Safety Assessment
The investigator specializes in evaluating therapeutic safety profiles and treatment tolerability in neurological interventions.
- Safety monitoring protocols
- Tolerability assessment
- Pharmacodynamic evaluation
Their expertise includes comprehensive safety assessments of novel therapeutic approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.